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Cells and Pathways
Of the multiple cell lineages undergoing reconsti-
tution in the setting of hematopoietic stem cell trans-
plantation (HSCT), this overview will focus on
reconstitution of the T cell arm of the immune system.
In clinical HSCT, the autologous setting is free of con-
straints imposed by reactions to allogeneic antigens,
but markers are lacking to distinguish reconstitution
from transferred cells versus stem or progenitor cells
left residual in the host. In allogeneic transplants, the
converse is true: the stem cell origins of the reconsti-
tuted populations can be determined, but the biology
of such reconstitution is confounded by concomitant
allogeneic responses. Because of these constraints,
the basic biology of T cell immune reconstitution
was first delineated in mouse models in which the
availability of congenic strains allowed stem cell ori-
gins of reconstituted cell populations to be investi-
gated without the presence of confounding allogenic
reactions. Two pathways of T cell regeneration were
identified: the thymic-dependent maturation of new
T cells from marrow progenitors, and thymic-
independent expansion of mature peripheral T cells
[1]. These initial studies also determined that no other
pathways existed by which substantial peripheral pop-
ulations of T cells were generated, and also established
a means for investigating T cell reconstitution in
humans by analyzing the expression of isoforms of
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the pathway of regeneration. They also demonstrated
that homeostatic expansion of mature T cells occurred
in lymphopenic hosts. Studies of such expansion have
formed central concepts of homeostasis: that T cell
levels are maintained by a balance between cytokine-
consuming cells and homeostatic cytokines that sup-
port the maturation, proliferative expansion, and
survival of T cells [2].
In translating these murine findings to humans, the
recovery of CD41 T cells in pediatric patients who
were severely lymphopenic following chemotherapy
treatment were initially tracked (Figure 1). There
was a strong correlation between the recovery of total
CD41 T cell numbers and the recovery of naive,
CD45RA1CD45RO2 CD41 T cells after as few as 6
months [3]. Furthermore, recovery of naive CD41
cells was associated with amarked expansion of thymus
volume, consistent with a dynamic regulation of the
thymus. Finally, an inverse correlation was observed
between age and early recovery of CD41 T cells in
the peripheral blood (PB). These data supported the
conclusion that thymic-dependent T cell production
was primarily responsible for the repopulation of PB
CD41 T cells in young patients following acute T
cell depletion associated with therapy. Most impor-
tantly, this work confirmed that the approach of utiliz-
ing CD45 isoform expression on CD41 T cells, as
established from murine basic research, could be
used to investigate immune reconstitution in humans.
To assess the contributions of thymus-dependent
and -independent pathways in adults, CD45 isoforms
expressed by CD41 T cells following chemotherapy
were characterized [4]. In contrast to observations in
pediatric patient populations, lymphopenic adults
(aged over 30 years) generated few new CD45RA1
CD41 cells during the first year posttherapy. Instead,
CD45RO1 CD41 cells increased rapidly in number,
recovering the majority of CD41 T cells to pretreat-
ment levels within the first 3 months after chemother-
apy [5]. Thus, these studies established the existence of
an early second primary pathway of CD41 T cell
regeneration in humans, namely, a thymus indepen-
dent, peripheral expansion pathway marked by pro-
duction of T cells of memory phenotype. TheseS133
Figure 1. Model representing the posttransplant time course of CD41
T cell recovery in a patient with a robust renewal of thymopoiesis. Thy-
mic enlargement peaks at 12 months posttransplant and is accompanied
by an increasing number of CD45RA1CD62L1 naive and TREC-bearing
cells in the second year. Recovery of TCR repertoire diversity in the
memory subpopulations follows and is dependent upon recovery of ad-
equate numbers of naive cells.
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tion in adults over prolonged periods of time.
In characterizing T cell reconstitution in adults
over prolonged periods of time, it was confirmed that
early recovery of CD41 T cells following autologous
HSCT consisted primarily of cells with an activated
(HLA-DR1) effector memory (CD62L– CCR7–
CD45RA–) phenotype, but that this peripheral expan-
sion only transiently increased the peripheral T cell
population [6]. In contrast, a renewal of thymopoie-
sis—as assessed by naı¨ve cells, TREC frequency, thy-
mus size, and repertoire rediversification—resulted in
recovery of normal numbers of total CD41 T cell
levels by the end of the second year. When thymopoi-
esis was not reactivated, levels of total CD4 cells
remained below normal even 4 to 5 years after trans-
plant. Furthermore, thymus-dependent CD4 produc-
tion reestablished central memory (CM) populations,
identified as CD62L1 CCR71 CD45RA– [6]. Thus,
the recovery of substantial thymus activity was neces-
sary for CD41 T cell reconstitution over time.
In studying the recovery of CD81 T cells over
a prolonged time period after autologous HSCT, it
was observed that the kinetics of repopulation differed
markedly from that of CD41 T cells. Four patterns of
CD81 T cell recovery were identified. In the first,
found in more than half of the patients, the CD282
CD81 cells not only expanded as a massive early spike
in total CD8 numbers, but were the dominant ele-
ments in persistently elevated CD8 populations
observed throughout the first 2 years posttransplant.
Furthermore, these CD282 cells had a limited oligo-
clonal T cell receptor (TCR) repertoire that also
was consistent over time, and because of the high pro-
portion of these cells, dominated the overall spectra-
type of the CD8 cells. It was found that a recovery
pattern dominated by a disproportionate expansion
of CD282 (effector memory) CD8 cells correlated
with cytomegalovirus (CMV) IgG seropositive statuspretreatment. A second pattern, observed in
approximately one-third of the patients, bore more
resemblance to CD41 T cell recovery. In this pattern,
phenotypically naı¨ve (CD281CD45RA1 CD11adull)
CD81 T cells gradually predominated in the second
year of recovery, providing the CD8 cells as a whole
with a broadly diverse TCR repertoire and high
TREC frequencies. A third subset of patients display-
ing features of both Patterns I and II was identified,
demonstrating that these were independent pathways
of recovery. Finally, a subset of patients displayed
a fourth pattern. These lackedmajor increases in either
early effector populations or late recovery of naı¨ve
CD81 T cells; the total numbers of CD8 cells
remained low and total repertoire diversity was limited
throughout the follow-up period. The observation of
severe long-term deficits in total numbers and in
repertoire diversity in both CD4 and CD8 numbers
demonstrated the limits of homeostatic expansion in
adults.
Cytokines
It has been found that blood levels of IL-7 and
IL-15 follow the pattern of a determining homeostatic
cytokine. For example, in patients undergoing T cell-
replete allogeneic transplant for treatment of leukemia
or lymphoma, plasma levels of IL-15 increase during
each successive round of cyto-reductive adjuvant ther-
apy, reaching a 50- to 100-fold increase on the day of
transplant, the days of greatest CD8 and NK
depletion. Concurrent with the rapid recovery of NK
and CD81memory T cells, IL-15 levels in the PB de-
creased. This inverse correlation of cells and cytokine
is consistent with the consumption kinetics of a ho-
meostatic cytokine.
IL7 is also a primary homeostatic cytokine for gen-
eral T cell populations [7,8]. It is the first of the pri-
mary homeostatic cytokines to be identified as such,
and is the first to be introduced into clinical trials. In
these trials, rhIL-7 produced a marked dose-depen-
dent increase in the numbers of circulating CD41
and CD81T cells, which persisted in follow-up assays
at 6 to 12 weeks post treatment [4,9]. Furthermore,
rhIL-7 therapy disproportionately increased CCR71
CD271CD45RA1naive andCCR71CD271CD45RA2
CMcells,which represent themost diverse components
of the mature TCR pool. Because of the extent of this
population shift, IL-7 administration led to an overall
increase in TCR diversity in CD41 and CD81T cells.
Thus, rhIL-7 can induce thymus-independent T cell
growth in naı¨ve and CM populations and enhance rep-
ertoire diversity in peripheral T cell populations.
Regulation of Thymopoiesis
As noted, prolonged lymphopenia is associated
with return of enhanced thymus function in some
adults. Insulin-like growth factor (IGF-1) is a known
Biol Blood Marrow Transplant 16:S133-S137, 2010 S135Immune Reconstitutionregulator of thymic function; exogenous IGF-1 has
been shown to affect thymic and peripheral T cell pop-
ulations in murine bone marrow transplant (BMT)
models [10,11]. Current studies indicate that IGF-1
controls thymic function through its effect on thymic
epithelial cells (TEC). Similarly, KGF enhances thy-
mopoiesis through receptors expressed by TEC [12-
15]. Recently, it has been shown that interruption of
androgen signaling [16] exerts its effect to enhance
thymus activity in the transplant setting by increased
expression of CCL25, a molecule important for the
immigration of thymocytes precursors from BM into
the thymus [17]. Taken together, these 3 molecules,
which increase thymus production of T cells, indicate
that thymus epithelial cells constitute a primary site of
control with respect to modulation of thymus func-
tion. Naturally occurring pathways of such regulation
remain largely uncharacterized.
What’s Broken and Why It Matters
Impaired CD4 1 T cell reconstitution after
allogeneic SCT
The reconstitution of effective T cell immunity is 1
of the most important elements of successful allo-
geneic SCT. The most problematic element in T cell
reconstitution is the restoration of functionally com-
petent donor-derived CD41 T cells, which is critical
for the prevention of opportunistic infections and is
most directly affected by the development of graft-ver-
sus-host disease (GVHD). Defects in thymic produc-
tion and peripheral homeostatic expansion have both
been shown to contribute to the impairment in
CD41 T cell regeneration [18,19]. With respect to
the former, the generation of new CD41 T cells has
been shown to be constrained by direct thymic damage
resulting from the conditioning regimen and/or age-
related involution [20,21]. Additionally, in patients
with GVHD, thymic production of naive T cells is fur-
ther compromised because of direct T cell-mediated
epithelial damage along with the reduced production
of cytokines necessary for thymopoiesis [15,22]. This
places a larger burden on mature CD41 T cells that
are transferred with the BM graft for the maintenance
of T cell immunity. GVHD, however, also deleteri-
ously affects expansion of these cells in the periphery
of transplant recipients [23]. This has been attributed
to the propensity of these cells to have shortened sur-
vival [24,25], and to bemore prone to undergo apopto-
tic cell death [26,27] because of the overexpression
of death receptors and the underexpression of pro-
survival protein (ie, bcl-2, bcl-XL). Why expansion
and survival of CD41 T cells is impaired, particularly
in the setting of GVHD, is still not well under-
stood. Aside from the effects of GVHD itself, the
administration of immune suppressive agents, such as
calcineurin inhibitors, steroids, and other drugs foreither prevention or treatment of GVHD may also
affect immune reconstitution after allogeneic HSCT.
CD4 1 T cell reconstitution in the periphery is
constrained by the host microenvironment
A central question in understanding the failure of
effective CD41 T cell reconstitution in the periphery
is whether the quantitative reduction in CD41 T cell
numbers is because of an intrinsic defect in these cells
or whether the environmental milieu that arises from
GVHD deleteriously affects CD41 T cell expansion.
To address this question, several studies have em-
ployed adoptive transfer models to assess the capability
of T cells from GVHD recipients to survive when
removed from their original environment. Dulude
and colleagues [7] demonstrated that host-tolerant T
cells have a limited capability to expand when trans-
ferred into GVHD mice. In contrast, T cells obtained
from animals undergoing GVHD were competent to
expand in thymectomized secondary hosts, supporting
the premise that these T cells were capable of signifi-
cant expansion once removed from the GVHDmilieu.
Additional work by Gorski et al. [28] has shown that
the adoptive transfer of GVHD splenic T cells into ir-
radiated hosts of the same major histocompatibility
complex (MHC) type as the original recipient results
in a marked attenuation of GVHD coupled with the
expansion of donor-derived T cells and restoration of
normal CD4/CD8 ratios. Moreover, using CDR3
spectratyping as an approach to examine the T cell
repertoire, these studies demonstrated that the reper-
toire skewing and contraction that is characteristic of
GVHD is not a fixed defect. Rather, T cells from
GVHD animals were capable of significant molecular
diversity after their transfer into secondary hosts.
These data indicate that skewing and holes in the T
cell repertoire are not necessarily fixed in GVHD ani-
mals, but rather subdominant T cell populations per-
sist in these mice and have the capacity for expansion
and the ability to contribute to normalization of the
T cell repertoire once they are removed from the
GVHD milieu. Collectively, these studies strongly
suggest that the defects in the GVHD microenviron-
ment are responsible for quantitative and qualitative
failure of effective CD41T cells reconstitution during
GVHD.
Critical molecules necessary for CD41 T cell
survival
The major survival signals that have been identi-
fied for both naive and memory CD41 T cells are
cytokines and MHC molecules [29]. With respect to
cytokines, as noted, IL-7 has been shown to play the
pivotal role in T cell homeostasis and is necessary for
survival of CD41 T cells [29,30]. Several lines of evi-
dence, however, argue against a deficiency of IL-7
S136 Biol Blood Marrow Transplant 16:S133-S137, 2010R. E. Gress et al.being responsible for the impaired CD41T cell recon-
stitution observed during GVHD. First of all, IL-7
levels have been shown to be markedly elevated in
recipients undergoing GVHD [31]. Furthermore,
administration of IL-7 in experimental GVHDmodels
has not been shown to enhance CD41 T cell reconsti-
tution [32,33]. Finally, recent data indicate that high
levels of stromal cell-derived IL-7 actually function
in a negative feedback loop to curtail homeostatic
expansion of CD41 T cells [34]. Thus, these data
lead one to conclude that deprivation of IL-7 per se
does not appear to be an adequate explanation for
the impaired reconstitution of these cells.
Although naı¨ve T cells require self-peptide/MHC
signals for survival [35], memory T cells do not share
this requirement, although the lack of MHC ligands
may affect memory T cell function [36]. Destruction
of lymphoid niches by GVHD or reductions in the
numbers of class II expressing cells in the periphery
may therefore inhibit T cell:MHC contacts necessary
for survival, and is a potential explanation for the ob-
served reduction in CD41T cells. Recent studies indi-
cate that dendritic cells appear to be a likely candidate
based on data demonstrating that an increase in
CD11c1 cells is associated with increased homeostatic
expansion of CD41T cells. In fact, work by Guimond
et al. [34] has demonstrated that IL-7 production by
BM-derived dendritic cells (DCs) binds to IL-7R1 ex-
pressed on CD41 T cells and leads to the homeostatic
expansion of these cells under lymphopenic condi-
tions. Plasmacytoid DCs, in particular, may be primar-
ily responsible for regulating the CD4 T cell niche,
which is of potential clinical significance given data
showing that a deficiency of these cells is associated
with impaired T cell reconstitution and an increase
in transplant-related mortality [37].
Blockade of IL-6 signaling results in a
recalibration of effector and regulatory CD41 T cells
Although amajor goal in allogeneic SCT is the res-
toration of normal numbers of CD41 T cells, the spe-
cific subset composition of these cells may also be
critical in the reestablishment of functional T cell im-
munity. GVHD is characterized by the preponderance
of effector CD41 T cells (eg, T helper cell (Th)1 and
Th17) that are capable of secreting inflammatory cyto-
kines or mediating direct tissue damage [38]. In con-
trast, a majority of studies have shown that CD41
foxp31 regulatoryT cells (Tregs) that serve tomitigate
inflammatory responses are significantly reduced in
GVHD recipients [39,40]. This resulting imbalance
in the ratio of effector to Tregs contributes to the
proinflammatory milieu. Cytokines that are produced
during GVHD have been shown to be critical in di-
recting the differentiation of naı¨ve T cells to either ef-
fector T cells or Tregs. IL-6 is of particular interestwith respect to GVHD biology because it occupies
a unique position at the crossroads where the fate of
naı¨ve T cells to become either regulatory cells or
proinflammatory T cells is determined. In the pres-
ence of IL-6 and transforming growth factor-
b (TGF-b), naı¨ve T cells differentiate into Th17 cells,
whereas in its absence, these same cells are induced to
become Tregs [41]. The question of whether blockade
of IL-6 signaling would alter the subset composition of
CD41 T cells in GVHD recipients was therefore
examined. These studies revealed that treatment of
recipient mice with an anti-IL-6R antibody signifi-
cantly prolonged survival and inhibited the severity
of GVHD [42]. This was attributable to marked in-
crease in regulatory T cells that occurred in both thy-
mic-dependent and thymic-independent manners.
Moreover, it was observed that a commensurate reduc-
tion in the absolute number of proinflammatory Th1
and Th17 cells in GVHD target organs occurred.
Thus, overproduction of IL-6 during GVHD results
in a qualitative imbalance in CD41 T cells toward an
effector phenotype, whereas blockade of IL-6 signal-
ing serves to recalibrate the effector and regulatory
arms of the immune system and thereby mitigate the
severity of GVHD. These studies therefore indicate
that in addition to impairment of immune reconstitu-
tion in the setting of GVHD, a second link of the 2 ex-
ists in that the successful reconstitution of certain
subpopulations and functions can decrease the severity
of GVHD.
Further understanding of the mechanisms that
hinder the reconstitution of CD41 T cells in alloge-
neic SCT recipients, in particular those with
GVHD, will hopefully lead to more effective strategies
that will result in improved immune competence.
Likewise, increased information regarding the com-
plex interactions of reconstituted subsets of T cells
and allo-aggressive responses in the setting of alloge-
neic HSCT should give rise to new strategies for pre-
vention of GVHD.ACKNOWLEDGMENTS
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